Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR.


Previously studies have shown that tumor-homing peptide NGR enhances the therapeutic efficacy of human interferon α2a (IFNα2a) against tumors. Here we investigated in vivo anti-tumor effect of recombinant human IFNα2a-NGR (rhIFNα2a-NGR) against human lung adenocarcinoma cell line SPC-A-1, A549 and murine Lewis lung carcinoma (LLC) subcutaneously xenografted… (More)
DOI: 10.1016/j.yrtph.2011.02.007



Citations per Year

Citation Velocity: 17

Averaging 17 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Zhang2011AntitumorEA, title={Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR.}, author={Baolai Zhang and Bei Gao and Shuhong Dong and Yingqi Zhang and Yongjie Wu}, journal={Regulatory toxicology and pharmacology : RTP}, year={2011}, volume={60 1}, pages={73-8} }